Evidence for differences in regioselective and stereoselective glucuronidation of silybin diastereomers from milk thistle (Silybum marianum) by human UDP-glucuronosyltransferases

References

• Baer-Dubowska W, Szaefer H, Krajka-Kuzniak V. (1998). Inhibition of murine hepatic cytochrome P450 activities by natural and synthetic phenolic compounds. Xenobiotica 28:735–743.
   PubMed Web of Science ®Google Scholar
• Bartholomaeus AR, Bolton R, Ahokas JT. (1994). Inhibition of rat liver cytosolic glutathione S-transferase by silybin. Xenobiotica 24:17–24.
   PubMed Web of Science ®Google Scholar
• Cashman JR, Perotti BY, Berkman CE, Lin J. (1996). Pharmacokinetics and molecular detoxication. Environ Health Perspect 104 (Suppl 1):23–40.
   Google Scholar
• Chen Y, Xie S, Chen S, Zeng S. (2008). Glucuronidation of flavonoids by recombinant UGT1A3 and UGT1A9. Biochem Pharmacol 76:416–425.
   PubMed Web of Science ®Google Scholar
• Cheng Z, Radominska-Pandya A, Tephly TR. (1999). Studies on the substrate specificity of human intestinal UDP-glucuronosyltransferases 1A8 and 1A10. Drug Metab Dispos 27:1165–1170.
   PubMed Web of Science ®Google Scholar
• Flaig TW, Glodé M, Gustafson D, van Bokhoven A, Tao Y, Wilson S, Su LJ, Li Y, Harrison G, Agarwal R, Crawford ED, Lucia MS, Pollak M. (2010). A study of high-dose oral silybin–phytosome followed by prostatectomy in patients with localized prostate cancer. Prostate 70:848–855.
   PubMed Web of Science ®Google Scholar
• Gaiser BK, Lockley DJ, Staines AG, Baarnhielm C, Burchell B. (2003). Almokalant glucuronidation in human liver and kidney microsomes: evidence for the involvement of UGT1A9 and 2B7. Xenobiotica 33:1073–1083.
   PubMed Web of Science ®Google Scholar
• Gažák R, Marhol P, Purchartová K, Monti D, Biedermann D, Riva S, Cvak L, Křen V. (2010). Large-scale separation of silybin diastereoisomers using lipases. Proc Biochem 45:1657–1663.
   Google Scholar
• Gažák R, Walterová D, Kren V. (2007). Silybin and silymarin–new and emerging applications in medicine. Curr Med Chem 14:315–338.
   PubMed Web of Science ®Google Scholar
• Gregory PA, Lewinsky RH, Gardner-Stephen DA, Mackenzie PI. (2004). Regulation of UDP glucuronosyltransferases in the gastrointestinal tract. Toxicol Appl Pharmacol 199:354–363.
   PubMed Web of Science ®Google Scholar
• Han YH, Guo D, Chen Y, Tan ZR, Zhou HH. (2009). Effect of continuous silymarin administration on oral talinolol pharmacokinetics in healthy volunteers. Xenobiotica 36:15–28.
   Google Scholar
• Han YH, Lou HX, Ren DM, Sun LR, Ma B, Ji M. (2004). Stereoselective metabolism of silybin diastereoisomers in the glucuronidation process. J Pharm Biomed Anal 34:1071–1078.
   PubMedGoogle Scholar
• Isom HC, Secott T, Georgoff I, Woodworth C, Mummaw J. (1985). Maintenance of differentiated rat hepatocytes in primary culture. Proc Natl Acad Sci USA 82:3252–3256.
   PubMed Web of Science ®Google Scholar
• Jančová P, Anzenbacherová E, Papousková B, Lemr K, Luzná P, Veinlichová A, Anzenbacher P, Simánek V. (2007). Silybin is metabolized by cytochrome P450 2C8 in vitro. Drug Metab Dispos 35:2035–2039.
   PubMed Web of Science ®Google Scholar
• Jones DR, Moran JH, Miller GP. (2010). Warfarin and UDP-glucuronosyltransferases: writing a new chapter of metabolism. Drug Metab Rev 42:55–61.
   PubMed Web of Science ®Google Scholar
• Josephy DP, Guengerich PF, Miners JO. (2005). “Phase I and Phase II” drug metabolism: terminology that we should phase out? Drug Metab Rev 37:575–580.
   PubMed Web of Science ®Google Scholar
• Kerdpin O, Knights KM, Elliot DJ, Miners JO. (2000). In vitro characterisation of human renal and hepatic frusemide glucuronidation and identification of the UDP-glucuronosyltransferase enzymes involved in this pathway. Ther Drug Monitor 22:10–13.
   PubMedGoogle Scholar
• Kiang TK, Ensom MH, Chang TK. (2005). UDP-glucuronosyltransferases and clinical drug–drug interactions. Pharmacol Ther 106:97–132.
   PubMed Web of Science ®Google Scholar
• Knights KM, Miners JO. (2010). Renal UDP-glucuronosyltransferases and the glucuronidation of xenobiotics and endogenous mediators. Drug Metab Rev 42:63–73.
   PubMed Web of Science ®Google Scholar
• Knights KM, Winner LK, Elliot DJ, Bowalgaha K, Miners JO. (2009). Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: inhibition by NSAIDs. Br J Clin Pharmacol 68:402–412.
   PubMed Web of Science ®Google Scholar
• Kosina P, Maurel P, Ulrichová J, Dvorák Z. (2005). Effect of silybin and its glycosides on the expression of cytochromes P450 1A2 and 3A4 in primary cultures of human hepatocytes. J Biochem Mol Toxicol 19:149–153.
   PubMed Web of Science ®Google Scholar
• Křen V, Gažák R, Puchartová K, Marhol P, Biedermann D, Sedmera P. (2009). Chemoenzymatic preparative separation of silybin A and B. J Mol Catal B: Enzymat 61:247251.
   Google Scholar
• Křen V, Ulrichová J, Kosina P, Stevenson D, Sedmera P, Prikrylová V, Halada P, Simánek V. (2000). Chemoenzymatic preparation of silybin beta-glucuronides and their biological evaluation. Drug Metab Dispos 28:1513–1517.
   PubMed Web of Science ®Google Scholar
• Lewinsky RH, Smith PA, Mackenzie PI. (2005). Glucuronidation of bioflavonoids by human UGT1A10: structure–function relationships. Xenobiotica 35:117–129.
   PubMed Web of Science ®Google Scholar
• Miners JO, Mackenzie PI, Knights KM. (2010). The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro–in vivo extrapolation of drug clearance and drug–drug interaction potential. Drug Metab Rev 42:196–208.
   PubMed Web of Science ®Google Scholar
• Pichard-Garcia L, Gerbal-Chaloin S, Ferrini JB, Fabre JM, Maurel P. (2002). Use of long-term cultures of human hepatocytes to study cytochrome P450 gene expression. Meth Enzymol 357:311–321.
   PubMed Web of Science ®Google Scholar
• Sridar C, Goosen TC, Kent UM, Williams JA, Hollenberg PF. (2004). Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. Drug Metab Dispos 32:587–594.
   PubMed Web of Science ®Google Scholar
• Strassburg CP, Nguyen N, Manns MP, Tukey RH. (1998). Polymorphic expression of the UDP-glucuronosyltransferase UGT1A gene locus in human gastric epithelium. Mol Pharmacol 54:647–654.
   PubMed Web of Science ®Google Scholar
• Strassburg CP, Oldhafer K, Manns MP, Tukey RH. (1997). Differential expression of the UGT1A locus in human liver, biliary, and gastric tissue: identification of UGT1A7 and UGT1A10 transcripts in extrahepatic tissue. Mol Pharmacol 52:212–220.
   PubMed Web of Science ®Google Scholar
• Tukey RH, Strassburg CP. (2001). Genetic multiplicity of the human UDP-glucuronosyltransferases and regulation in the gastrointestinal tract. Mol Pharmacol 59:405–414.
   PubMed Web of Science ®Google Scholar
• Tukey RH, Strassburg CP. (2000). Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40:581–616.
   PubMed Web of Science ®Google Scholar
• Wen Z, Dumas TE, Schrieber SJ, Hawke RL, Fried MW, Smith PC. (2008). Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract. Drug Metab Dispos 36:65–72.
   PubMed Web of Science ®Google Scholar
• Wong YC, Zhang L, Lin G, Zuo Z. (2009). Structure–activity relationships of the glucuronidation of flavonoids by human glucuronosyltransferases. Expert Opin Drug Metab Toxicol 5:1399–1419.
   PubMed Web of Science ®Google Scholar
• Wu JW, Lin LC, Hung SC, Lin CH, Chi CW, Tsai TH. (2008). Hepatobiliary excretion of silibinin in normal and liver cirrhotic rats. Drug Metab Dispos 36:589–596.
   PubMed Web of Science ®Google Scholar